Hepatitis B virus genotype has no impact on hepatitis B e antigen seroconversion after lamivudine treatment

doi:10.3748/wjg.v9.i12.2695

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 9, Issue 12

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2524)

All Articles published online

The chart showing PDF series, HTML series, Tables (1-3) series.

Item

Count

PDF

262

HTML

2145

Tables (1-3)

117

Sum=2524

Dec 15, 2003 (publication date) through Apr 29, 2024

Times Cited of This Article

Times Cited (43)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Viral Hepatitis

World J Gastroenterol. Dec 15, 2003; 9(12): 2695-2697
Published online Dec 15, 2003. doi: 10.3748/wjg.v9.i12.2695

Hepatitis B virus genotype has no impact on hepatitis B e antigen seroconversion after lamivudine treatment

Henry Lik-Yuen Chan, May-Ling Wong, Alex Yui Hui, Angel Mei-Ling Chim, Ada Mei-Ling Tse, Lawrence Cheung-Tsui Hung, Francis Ka-Leung Chan, Joseph Jao-Yiu Sung

Henry Lik-Yuen Chan, May-Ling Wong, Alex Yui Hui, Angel Mei-Ling Chim, Ada Mei-Ling Tse, Lawrence Cheung-Tsui Hung, Francis Ka-Leung Chan, Joseph Jao-Yiu Sung, Department of Medicine and Therapeutics, Chinese University of Hong Kong, Hong Kong

Author contributions: All authors contributed equally to the work.

Correspondence to: Dr. Henry Lik-Yuen Chan, Department of Medicine and Therapeutics, 9/F Prince of Wales Hospital, Shatin, Hong Kong. hlychan@cuhk.edu.hk

Telephone: +852-26323594 Fax: +852-26373852

Received: July 4, 2003
Revised: August 1, 2003
Accepted: October 8, 2003
Published online: December 15, 2003

Abstract

AIM: To investigate the association of hepatitis B virus (HBV) genotype and HBeAg seroconversion after nucleotide analogue treatment.

METHODS: Chronic hepatitis B patients receiving lamivudine followed up for at least 6 months post-treatment were studied. Consecutive treatment-naïve patients who were prospectively followed up in the clinic for at least 18 months were studied as controls. HBeAg seroconversion was defined as loss of HBeAg, appearance of anti-HBe and normalization of alanine aminotransferase for at least 6 months.

RESULTS: Thirty-five patients on lamivudine and 96 control patients followed up for 39 (18-49) months were studied. Lamivudine was given for 12 (10-18) months, and patients were followed up for 15 (6-34) months after drug cessation. Genotype B and C HBV were found in 43 and 88 patients and HBeAg seroconversion occurred in 12 (28%) and 16 (18%) patients, respectively (P = 0.30). There was no difference in HBeAg seroconversion between patients infected by genotype B and C HBV in the control (35% vs 21%, P = 0.25) and lamivudine-treated (14% vs 10%, P = 1.00) groups.

CONCLUSION: HBeAg seroconversion after treatment by lamivudine was not influenced by the HBV genotype.

Keywords: $[Keywords]